Pharmaceutical M&A

Laval-based Crescita Therapeutics Inc. (TSX: CTX) officially confirmed on March 14, 2026, that shareholders will receive a cash consideration of $0.80 per common share following the company’s acquisition by ClinActiv Holdings Inc. The all-cash arrangement marks a definitive exit for the dermatology-focused pharmaceutical firm as it integrates into the ClinActiv corporate structure. Background of the…